Lower EE - Search Results

1

Functional cooperation between co-amplified genes promotes aggressive phenotypes of HER2-positive breast cancer.

Yang Y, Leonard M, Luo Z, Yeo S, Bick G, Hao M, Cai C, Charif M, Wang J, Guan JL, Lower EE, Zhang X. Yang Y, et al. Among authors: lower ee. Cell Rep. 2021 Mar 9;34(10):108822. doi: 10.1016/j.celrep.2021.108822. Cell Rep. 2021. PMID: 33691110 Free PMC article.

2

HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical β-catenin signaling.

Ruiz-Torres SJ, Benight NM, Karns RA, Lower EE, Guan JL, Waltz SE. Ruiz-Torres SJ, et al. Among authors: lower ee. Oncotarget. 2017 Jul 22;8(35):58918-58933. doi: 10.18632/oncotarget.19441. eCollection 2017 Aug 29. Oncotarget. 2017. PMID: 28938607 Free PMC article.

3

HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1.

Yang Y, Leonard M, Zhang Y, Zhao D, Mahmoud C, Khan S, Wang J, Lower EE, Zhang X. Yang Y, et al. Among authors: lower ee. Cancer Res. 2018 Jan 15;78(2):422-435. doi: 10.1158/0008-5472.CAN-17-1533. Epub 2017 Nov 29. Cancer Res. 2018. PMID: 29187405 Free PMC article.

4

Reduced dose pegfilgrastim is associated with less bone pain without increased neutropenia: a retrospective study.

Lower EE, Charif M, Bartelt M. Lower EE, et al. Cancer Chemother Pharmacol. 2018 Jul;82(1):165-170. doi: 10.1007/s00280-018-3607-7. Epub 2018 Jun 5. Cancer Chemother Pharmacol. 2018. PMID: 29869680

5

Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistance.

Bick G, Zhang J, Lower EE, Zhang X. Bick G, et al. Among authors: lower ee. Cancer Drug Resist. 2022 Jun 1;5(2):498-510. doi: 10.20517/cdr.2022.33. eCollection 2022. Cancer Drug Resist. 2022. PMID: 35800368 Free PMC article. Review.

6

Plasma membrane phosphotyrosine, Her2-NEU, and epidermal growth factor receptor in human breast cancer. A comparative study.

Heffelfinger SC, Lower EE, Miller MA, Fenoglio-Preiser CM. Heffelfinger SC, et al. Among authors: lower ee. Am J Clin Oncol. 1996 Dec;19(6):552-7. doi: 10.1097/00000421-199612000-00003. Am J Clin Oncol. 1996. PMID: 8931669

7

A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer.

Mahtani R, Holmes FA, Badve S, Caldera H, Coleman R, Mamounas E, Kalinsky K, Kittaneh M, Lower E, Pegram M, Press MF, Rugo HS, Schwartzberg L, Vogel C; Breast Cancer Therapy Expert Group (BCTEG). Mahtani R, et al. Clin Breast Cancer. 2020 Jun;20(3):e251-e260. doi: 10.1016/j.clbc.2019.08.001. Epub 2019 Aug 21. Clin Breast Cancer. 2020. PMID: 32139271 Review.

8

CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells.

Wobus M, Rangwala R, Sheyn I, Hennigan R, Coila B, Lower EE, Yassin RS, Sherman LS. Wobus M, et al. Among authors: lower ee. Appl Immunohistochem Mol Morphol. 2002 Mar;10(1):34-9. doi: 10.1097/00129039-200203000-00006. Appl Immunohistochem Mol Morphol. 2002. PMID: 11893033

9

Bilateral synchronous breast cancer and HER-2/neu overexpression.

Safal M, Lower EE, Hasselgren PO, Hungness ES, Gazder P, Aron B, Shaughnessy EA, Yassin R. Safal M, et al. Among authors: lower ee. Breast Cancer Res Treat. 2002 Apr;72(3):195-201. doi: 10.1023/a:1014958514851. Breast Cancer Res Treat. 2002. PMID: 12058961

10

Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival.

Lower EE, Drosick DR, Blau R, Brennan L, Danneman W, Hawley DK. Lower EE, et al. Clin Breast Cancer. 2003 Jun;4(2):114-9. doi: 10.3816/cbc.2003.n.016. Clin Breast Cancer. 2003. PMID: 12864939

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

175 results

Search Page